|
鍾幸村（2013）。氧化壓力造成半乳糖老化大鼠中樞神經系統中的變化。中興大學獸醫學系暨研究所學位論文。台中市。
AM, S., WJ, S., D, S., and PH, G.-H. (1993). Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer’s disease. Neurology 43, 1467-1472.
Armstrong, R.A. (2013). What causes alzheimer’s disease? Folia Neuropathol 51, 169-188.
Bourdel-Marchasson, I. (2001). Antioxidant defences and oxidative stress markers in erythrocytes and plasma from normally nourished elderly Alzheimer patients. Age And Ageing 30, 235-241.
Caceres, A., and Kosik, K.S. (1990). Inhibition of neurite polarity by tau antisense oligonucleotides in primary cerebellar neurons. Nature 343, 461-463.
Chang, P., and Su, Y. (2000). Protocol for quantitative and qualitative analyses of the in vitro aggregation of synthetic β-amyloid. Brain Research Protocols 6, 6-12.
Chen JR, Wang TJ, Huang HY, Chen LJ, Huang YS, Wang YJ, Tseng GF (2009) Fatigue reversibly reduced cortical and hippocampal dendritic spines concurrent with compromise of motor endurance and spatial memory. Neuroscience. 161, 1104-1113
Dae-Hee Lee, Yong J Lee, and Kwon, K.H. (2010). Neuroprotective Effects of Astaxanthin in Oxygen-Glucose Deprivation in SH-SY5Y Cells and Global Cerebral Ischemia in Rat. Journal of Clinical Biochemistry and Nutrition 47, 121-129.
Dermaut, B., Kumar-Singh, S., Engelborghs, S., and Theuns, J. ( 2004). A novel presenilin 1 mutation associated with Pick's disease but not beta-amyloid plaques. Annals of Neurology 55, 617-626.
DM, M., and D, J. (1990). Deposition of amyloid (A4) protein within the brains of persons with dementing disorders other than Alzheimer's disease and Down's syndrome. Neuroscience Letters 109, 68-75.
Farrer, L., Cupples, L., l, J., and Haines (1997). Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease: A metaanalysis. JAMA The Journal of the American Medical Association 278, 1349-1356.
Francis, P.T., Palmer, A.M., Snape, M., and Wilcock, G.K. (1999). The cholinergic hypothesis of Alzheimer's disease: a review of progress. Journal of Neurology, Neurosurgery, and Psychiatry 66, 137-147.
Furman, J.L., Sama, D.M., and Norris, C.M. (2012). Targeting Astrocytes Ameliorates Neurologic Changes in a Mouse Model of Alzheimer’s Disease. Journal of the Society for Neuroscience 32, 16129-16149.
Giraldo, E., Lloret, A., Fuchsberger, T., and Viña, J. (2014). Aβ and tau toxicities in Alzheimer’s are linked via oxidative stress-induced p38 activation: Protective role of vitamin E. Redox Biology 2, 873-877.
Götz, J., Chen, F., and Nitsch, R.B.a.R.M. (2001). Tau Filament Formation in Transgenic Mice Expressing P301L Tau. The Journal of Biological Chemistry 276, 529-534.
Hebert, L.E., Weuve, J., Scherr, P.A., and Evans, D.A. (2013). Alzheimer disease in the United States (2010-2050) estimated using the 2010 Census. Neurology 80, 1778-1783.
Herrera, G., Turbat-Herrera, E., and Teng, J. (2011). Scanning/transmission electron microscopy to study how amyloid fibrils are extruded into the matrix. Amyloid 18, 24-26.
Higuera-Ciapara, Leticia Félix-Valenzuela, and Goycoolea, F.M. (2006). Astaxanthin: a review of its chemistry and applications. Critical Reviews in Food Science and Nutrition 46, 185-196.
Hishikawa, N., Takahashi, Y., and Krishna, U.K. (2012). Effects of turmeric on Alzheimer's disease with behavioral and psychological symptoms of dementia. Ayu 33, 499-504.
Hu, X., Crick, S., Bu, G., Frieden, C., Pappu, R. and Lee, J. (2009). Amyloid seeds formed by cellular uptake, concentration, and aggregation of the amyloid-beta peptide. Proceedings of the National Academy of Sciences, 106(48), pp.20324-20329.
Irvine, G.B., El-Agnaf, O., Walsh, D.M., and Shankar, G.M. (2008). Protein Aggregation in the Brain: The Molecular Basis for Alzheimer’s and Parkinson’s Diseases. Molecular Medicine 14, 451-464.
Jack, C.R., Jr, V.J.L., Weigand, S.D., and Wiste, H.J. (2009). Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain 132, 1355-1365.
Jean Soon Park, Jong Hee Chyun, and Kim, Y.K. (2010). Astaxanthin decreased oxidative stress and inflammation and enhanced immune response in humans. Nutrition & Metabolism 7, 18.
Kang, J., LEMAIRE, H.-G., UNTERBECK, A., SALBAUM, J.M., MASTERS, C.L., and KARL-HEINZ GRZESCHIK†, G.M., KONRAD BEYREUTHER & BENNO MÜLLER-HILL (1987). The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 325, 733-736.
Khan, R., Khan, M., and Sahreen, S. (2012). Brain antioxidant markers, cognitive performance and acetylcholinesterase activity of rats: efficiency of Sonchus asper. Behavioral And Brain Functions 8, 21.
Kim, T. S., Pae, C. U., Yoon, S. J., Jang, W. Y., Lee, N. J., Kim, J. J., ... & Lee, C. U. (2006). Decreased plasma antioxidants in patients with Alzheimer's disease. International journal of geriatric psychiatry, 21(4), 344-348.
L.Masters, C., Multhaup, G., Simms, G., and Pottgiesser, J. (1985). Neuronal origin of a cerebral amyloid: neurofibrillary tangles of Alzheimer's disease contain the same protein as the amyloid of plaque cores and blood vessels. . The EMBO Journal 4, 2757-2763.
Lecanu, L., Greeson, J., and Papadopoulos, V. (2005). Beta-Amyloid and Oxidative Stress Jointly Induce Neuronal Death, Amyloid Deposits, Gliosis, and Memory Impairment in the Rat Brain. Pharmacology 76, 19-33.
Lecanu, L., Rammouz, G., McCourty, A., Sidahmed, E., Greeson, J., and Papadopoulos, V. (2010). Caprospinol reduces amyloid deposits and improves cognitive function in a rat model of Alzheimer's disease. Neuroscience 165, 427-435.
Licinio, J., Prolo, P., M, S., and McCann (1999). Brain iNOS: current understanding and clinical implications. Molecular Medicine Today 5, 225-232.
Liu, Y., Fei Liu, Inge Grundke-Iqbal, and Gong, C.-X. (2011). Deficient brain insulin signalling pathway in Alzheimer's disease and diabetes. The Journal of Pathology 225, 54-62.
Masashiro Miyachi, Tomonori Matsuno, and Asano, K. (2015 ). Anti-inflammatory effects of astaxanthin in the human gingival keratinocyte line NDUSD-1. Journal of Clinical Biochemistry and Nutrition 56, 171-178.
Masliah, E., and Terry, R. (1993). The role of synaptic proteins in the pathogenesis of disorders of the central nervous system. . Brain Pathology 3, 77-85.
Mayeux, R., Saunders, A.M., Shea, S., and Mirra, S. (1998). Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer’s disease. The New England Journal of Medicine 338, 506-511.
Meng, H.-z., Ni, X.-f., and Shen, S.-r. (2017). Effects of astaxanthin on oxidative stress induced by Cu2+ in prostate cells. Journal of Zhejiang University Science B 18, 161-171.
Mitchell, A.J., and Shiri-Feshki, M. (2009). Rate of progression of mild cognitive impairment to dementia: Meta-analysis of 41 robust inception cohort studies. Acta Psychiatrica Scandinavica 119, 252-265.
Morrison, J.H., and Hof, P.R. (1997). Life and death of neurons in the aging brain. Science 278, 412-419.
Nishigaki, I., Rajendran, P., and Venugopal, R. (2009). Cytoprotective role of astaxanthin against glycated protein/iron chelate-induced toxicity in human umbilical vein endothelial cells. Phytotherapy research 24, 54-59.
Oddo, S., Caccamo, A., Kitazawa, M., Tseng, B.P., and LaFerla, F.M. (2003). Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease. Neurobiolology of Aging 24, 1063-1070.
Paola Palozza, Cristiana Torelli, Alma Boninsegna, and Rossella Simone, A.C., Maria Cristina Mele, Nevio Picci (2009). Growth-inhibitory effects of the astaxanthin-rich alga Haematococcus pluvialis in human colon cancer cells. Cancer Letters 283, 108-117.
Paula R Augusti, Andréia Quatrin, Sabrina Somacal, and Greicy MM Conterato, R.S., Amanda R Ruviaro, Luana H Maurer, Marta MF Duarte, Miguel Roehr and Tatiana Emanuelli (2012). Astaxanthin prevents changes in the activities of thioredoxin reductase and paraoxonase in hypercholesterolemic rabbits. Journal of Clinical Biochemistry and Nutrition 51, 42-49.
Pákáski, M., and Kálmán, J. (2008). Interactions between the amyloid and cholinergic mechanisms in Alzheimer's disease. Neurochemistry International 53, 103-111.
Penzes, P., Cahill, M.E., and Woolfrey, K.M. (2011). Dendritic spine pathology in neuropsychiatric disorders. Nature neuroscience 14, 285-293.
Reale, M., Kamal, M., Velluto, L., Gambi, D., Nicola, M., and Greig, N. (2012). Relationship between Inflammatory Mediators, Aβ Levels and ApoE Genotype in Alzheimer Disease. Current Alzheimer Research 9, 447-457.
Rita Mattei , Tatiana G. Polotow , Cristina V. Vardaris , and Beatriz A. Guerra , J.R.L., Rosemari Otton , Marcelo P. Barros (2011). Astaxanthin limits fish oil-related oxidative insult in the anterior forebrain of Wistar rats: Putative anxiolytic effects? Pharmacology, Biochemistry and Behavior 99, 349.
Robert G Fassett, and Coombes, J.S. (2009). Astaxanthin, oxidative stress, inflammation and cardiovascular disease. Future Cardiology 5, 333-342.
Robertson, R. (1998). Neonatal treatment with 192 IgG-saporin produces long-term forebrain cholinergic deficits and reduces dendritic branching and spine density of neocortical pyramidal neurons. Cerebral Cortex 8, 142-155.
Rodriguez-Vieitez, E., Saint-Aubert, L., and Nordberg, A. (2016). Diverging longitudinal changes in astrocytosis and amyloid PET in autosomal dominant Alzheimer’s disease. Brain 139, 922-936.
Saido, T. and Leissring, M. (2012). Proteolytic Degradation of Amyloid -Protein. Cold Spring Harbor Perspectives in Medicine, 2(6), pp.a006379-a006379.
Saunders, A., WJ, S., D, S., and PH, G.-H. (1993). Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer’s disease. Neurology 43, 1467-1472.
Shankar, G.M., Li, S., and Selkoe, D.J. (2008). Amyloid β-Protein Dimers Isolated Directly from Alzheimer Brains Impair Synaptic Plasticity and Memory. Nature medicine 14, 937-842.
Solito, E., and Sastre, M. (2012). Microglia Function in Alzheimer’s Disease. Frontiers in Pharmacology 3, 14.
Sterniczuk, R., Antle, M., LaFerla, F., and Dyck, R. (2010). Characterization of the 3xTg-AD mouse model of Alzheimer's disease: Part 2. Behavioral and cognitive changes. Brain Research 1348, 149-155.
Tanaka, N., Ikeda, Y., Ohta, Y., Deguchi, K., Tian, F., Shang, J., Matsuura, T., and Abe, K. (2011). Expression of Keap1–Nrf2 system and antioxidative proteins in mouse brain after transient middle cerebral artery occlusion. Brain Research 1370, 246-253.
Takashi Maoka, Harukuni Tokuda, Nobutaka Suzuki, Hideaki Kato, and Etoh, H. (2012). Anti-oxidative, anti-tumor-promoting, and anti-carcinogensis activities of nitroastaxanthin and nitrolutein, the reaction products of astaxanthin and lutein with peroxynitrite. Marine Drugs 10, 1391-1399.
Tara L. Spires, Meyer-Luehmann, M., and Hyman, B.T. (2005). Dendritic spine abnormalities in amyloid precursor protein transgenic mice demonstrated by gene transfer and intravital multiphoton microscopy. Journal of Neuroscience 25, 7278-7287.
Tackenberg, C., Grinschgl, S., Trutzel, A., Santuccione, A., Frey, M., Konietzko, U., Grimm, J., Brandt, R., and Nitsch, R. (2013). NMDA receptor subunit composition determines beta-amyloid-induced neurodegeneration and synaptic loss. Cell Death And Disease 4, e608.
Terao, J. (1989). Antioxidant activity of beta-carotene-related carotenoids in solution. Lipids 24, 659-661.
Texidó, L., Martín-Satué, M., Alberdi, E., Solsona, C., and Matute, C. (2011). Amyloid β peptide oligomers directly activate NMDA receptors. Cell Calcium 49, 184-190.
Upadhaya, A., Lungrin, I., Yamaguchi, H., Fändrich, M., and Thal, D. (2012). High-molecular weight Aβ oligomers and protofibrils are the predominant Aβ species in the native soluble protein fraction of the AD brain. Journal Of Cellular And Molecular Medicine 16, 287-295.
Wanqiang Wu, Xin Wang, Qisen Xiang, Xu Meng, and Ye Peng, N.D., Zhigang Liu, Quancai Sun, Chan Wang and Xuebo Liu (2014). Astaxanthin alleviates brain aging in rats by attenuating oxidative stress and increasing BDNF levels. Food Funct 5, 158-166.
W J.P. Henneman, Sluimer, and Barkhof, F. (2009). Hippocampal atrophy rates in Alzheimer disease. Neurology 72, 999-1007.
Webster, S.J., Bachstetter, A.D., and Nelson, P.T. ( 2014). Using mice to model Alzheimer's dementia: an overview of the clinical disease and the preclinical behavioral changes in 10 mouse models. Frontiers in Genetics 5, 88.
Wisniewski, T., J, G., and B., F. (1991). Peptides homologous to the amyloid protein of Alzheimer's disease containing a glutamine for glutamic acid substitution have accelerated amyloid fibril formation. Biochem Biophys Res Commun 179, 1247-1254.
Yan Xue, Zhenzhen Qu, Jian Fub, Junli Zhen, and Wenjing Wang, Y.C., Weiping Wang, (2017). The protective effect of astaxanthin on learning and memory deficits and oxidative stress in a mouse model of repeated cerebral ischemia/reperfusion. Brain Research Bulletin 131, 221-228.
Yang, Z., Zhang, K., Lin, P.-J., and Atherly, A.J. (2012). A longitudinal analysis of the lifetime cost of dementia. Health Serv Res 47, 1660-1678.
Yuan, X., Guo, X., Deng, Y., Zhu, D., Shang, J., and Liu, H. (2015). Chronic intermittent hypoxia-induced neuronal apoptosis in the hippocampus is attenuated by telmisartan through suppression of iNOS/NO and inhibition of lipid peroxidation and inflammatory responses. Brain Research 1596, 48-57.
Ziad S. Nasreddine MD, A., N., and PhD, P. (2005). The Montreal Cognitive Assessment, MoCA: A Brief Screening Tool For Mild Cognitive Impairment. Journal of the American Geriatrics Society 53, 695-699.
|